Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.56
+0.48 (5.94%)
At close: Sep 16, 2025, 4:00 PM EDT
8.60
+0.04 (0.47%)
After-hours: Sep 16, 2025, 7:56 PM EDT
Novavax Revenue
Novavax had revenue of $239.24M in the quarter ending June 30, 2025, a decrease of -42.42%. This brings the company's revenue in the last twelve months to $1.08B, up 9.22% year-over-year. In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%.
Revenue (ttm)
$1.08B
Revenue Growth
+9.22%
P/S Ratio
1.28
Revenue / Employee
$1,133,107
Employees
952
Market Cap
1.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NVAX News
- 12 days ago - Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 12 days ago - Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment - PRNewsWire
- 13 days ago - Novavax to Participate in the Cantor Global Healthcare Conference - PRNewsWire
- 20 days ago - Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. - PRNewsWire
- 26 days ago - Novavax Announces Convertible Debt Refinancing - PRNewsWire
- 5 weeks ago - Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Novavax beats quarterly revenue estimates on milestone payment - Reuters
- 5 weeks ago - Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire